Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 26
---
 Sale        
 of the Purchase Shares to the 
 Selling                       
 Shareholder (3)               |            |
|:-----------------|--------:|:----|:--------------------------------------|-----------:|:----|:------------------------------------------------------------|:------|:----|:------------------------------|-----------:|
| $                |    1.00 |     |                                       | 35,000,000 |     |                                                             | 98.1% |     | $                             | 35,000,000 |
| $                | 4.13(4) |     |                                       |  8,474,576 |     |                                                             | 92.7% |     | $                             | 35,000,000 |
| $                |    5.00 |     |                                       |  7,000,000 |     |                                                             | 91.3% |     | $                             | 35,000,000 |
| $                |   10.00 |     |                                       |  3,500,000 |     |                                                             | 84.0% |     | $                             | 35,000,000 |
| $                |   15.00 |     |                                       |  2,333,333 |     |                                                             | 77.7% |     | $                             | 34,999,995 |

__________________

| (1) | The purchase price assumes a discount to the market price of our shares, in accordance with the terms 
 of the Purchase Agreement.                                                                            |

| (2) | The denominator is based on 6,685,918,922 Ordinary Shares outstanding as of January 15, 2025, adjusted                                          
 to include the issuance of the number of Purchase Shares set forth in the adjacent column which we would have issued to the Selling Shareholder 
 based on the applicable assumed purchase price per share.                                                                                       |

| (3) | We will not receive any proceeds from the issuance of any Commitment Shares if issued to the Selling Shareholder                       
 to release the Company of its liability to pay the Commitment Fee. The proceeds reflected in this column would be reduced by an amount 
 equal to the product of the final Commitment Shares multiplied by the assumed purchase price per Depositary Share.                     |

| (4) | Represents the last reported sales price of our Depositary Shares on January 16, 2024, as reported by 
 NASDAQ, less a 5% discount.                                                                           |

| 17 |

<div align='center